TIL therapy

TIL therapy is approved by the U.S. Food and Drug Administration for patients with advanced melanoma. At UChicago Medicine, we are also testing TIL therapy in a clinical trial for patients with cervical cancer. Our physician-researchers also plan to study this treatment for other types of solid tumors in future clinical trials.

If you qualify, you will only have TIL therapy one time. If you respond to this treatment, your new T cells will continue to fight cancer cells in your body.

During your conditioning chemotherapy and for a few weeks after your TIL therapy, you should take some common-sense precautions to avoid infections. For example, you should wash your hands frequently and avoid exposure to young children, if possible. You do not need to isolate yourself at home.

TIL therapy takes several weeks. This timeframe includes your surgery, the preparation of your new TILs, your conditioning chemotherapy and your infusion. Your medical oncologist will go over this timeframe in detail with you.